ashley dunham semaglutide A woman who lost 100 pounds on shared 3 ways the holiday season has changed — including not feeling the need to diet in the new year Dr. Whitney Dunham, MD |

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

Aim for 80-100g protein daily minimum

Notably, CagriSema is the only one of the three that brings in the amylin system the others stay within the incretin/glucagon family

Behoefte aan meer supplementen

Some states apply the discovery rule, which extends the filing deadline to when a reasonable person would have discovered the medication caused their injuries, potentially providing additional time for patients who didnt immediately connect their symptoms to Ozempic use

However: Patients with BMI over 45 Severe sleep apnea Advanced type 2 diabetes Longstanding obesity may achieve more durable remission through bariatric surgery